Samil Pharmaceutical Co.,Ltd

KOSE:A000520 Stock Report

Market Cap: ₩273.9b

Samil PharmaceuticalLtd Valuation

Is A000520 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A000520 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A000520's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A000520's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A000520?

Key metric: As A000520 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A000520. This is calculated by dividing A000520's market cap by their current revenue.
What is A000520's PS Ratio?
PS Ratio1.3x
Sales₩212.42b
Market Cap₩273.86b

Price to Sales Ratio vs Peers

How does A000520's PS Ratio compare to its peers?

The above table shows the PS ratio for A000520 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
A041960 Komipharm International
5xn/a₩275.4b
A003220 Daewon Pharmaceutical
0.5x9.2%₩312.7b
A243070 Huons
0.5x9.8%₩299.8b
A084110 Huons Global
0.5xn/a₩353.0b
A000520 Samil PharmaceuticalLtd
1.3xn/a₩273.9b

Price-To-Sales vs Peers: A000520 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does A000520's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$158.67m
A002620 Jeil Pharma Holdings
0.2xn/aUS$92.36m
A000230 Ildong Holdings
0.1xn/aUS$57.08m
No more companies available in this PS range
A000520 1.3xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A000520 is expensive based on its Price-To-Sales Ratio (1.3x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A000520's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A000520 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A000520's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩129,100.00

7D

4.7%

1Y

-41.2%

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩265,000.00

7D

-1.3%

1Y

69.8%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,650.00

7D

1.7%

1Y

n/a